Gensia Sicor Gets FDA OK for Cancer Drug
- Share via
Dow Jones
Sicor Inc. said Monday that its Gensia Sicor Pharmaceuticals Inc. unit received Food and Drug Administration approval to sell a generic version of a drug that treats breast, ovarian and certain bladder carcinomas and various lymphomas.
The Irvine specialty pharmaceutical company said in a news release that the government approved the sale of its Thiotepa injectable drug.
Sicor stock lost 15 cents to close at $10.51 a share on Nasdaq.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
